Summary
KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.91 per share a year ago.
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Q1 2026 Earnings Call September 11, 2025 8:30 AM EDT Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Paul Audhya - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Will Soghikian - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Serge Belanger - Needham & Company, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to KalVista Pharmaceuticals operational update and First Fiscal Quarter Financial Results.
KalVista Pharmaceuticals Inc. (KALV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has KalVista Pharmaceuticals Inc. ever had a stock split?
KalVista Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Benjamin L. Palleiko CEO | NASDAQ (NMS) Exchange | 483497103 CUSIP |
| US Country | 150 Employees | - Last Dividend | 22 Nov 2016 Last Split | 9 Apr 2015 IPO Date |
Overview
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors to address diseases with significant unmet medical needs in the United States. With its headquarters located in Cambridge, Massachusetts, the company is dedicated to pushing the boundaries of medical research to bring forward innovative therapies that can improve the lives of patients facing challenging conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME).
Products and Services
- Sebetralstat: This is a novel small molecule plasma kallikrein inhibitor that is entering the Phase 3 KONFIDENT trial. It represents a potential oral, on-demand therapy for HAE attacks. The development of Sebetralstat underscores KalVista's commitment to providing alternative treatment solutions for patients struggling with hereditary angioedema, offering hope for more control over their condition with an orally administered medication.
- Factor XIIa Oral Inhibitor Program: Currently in the preclinical stage, this oral inhibitor targets the Factor XIIa enzyme, which plays a critical role in the pathophysiology of HAE. By focusing on this novel target, KalVista aims to pioneer a different approach to managing HAE, paving the way for potentially more effective and patient-friendly treatments in the future.
Contact Information
